INTRODUCTION
============

Imatinib is a selective tyrosine kinase inhibitor and it is widely used as an anticancer drug primarily in Philadelphia-chromosome-positive chronic myeloid leukemia and gastrointestinal stromal tumor \[[@B1][@B2]\]. Besides its well documented anticancer actions, scientists have identified its therapeutic potential in diseases affecting the brain such as Alzheimer disease, Parkinson disease, multiple stroke and brain hemorrhage etc. \[[@B3][@B4][@B5]\]. Moreover, its potential in preventing the damage to the blood brain barrier in different animal models has been reported \[[@B6][@B7][@B8][@B9][@B10]\]. However, its role and mechanisms in global cerebral ischemia-reperfusion-induced impairment in motor activity, learning and memory deficits and cerebral infarction is not explored. A state of global cerebral ischemia-reperfusion injury in rodents mimics the situation of severe shock in patients due to cardiac arrest or severe hypotension \[[@B11][@B12]\]. Accordingly, a rodent model of global ischemia reperfusion-induced injury was employed to explore the neuroprotective role of imatinib.

Janus-activated kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) constitute an important signaling pathway in the brain. Indeed, the activation of JAK2 leads to phosphorylation of STAT3, which is translocated to nucleus to serve as a transcriptional factor. Studies have reported the significant role of JAK2/STAT3 in the different brain diseases, particularly in ischemic brain disease. The role of JAK2/STAT3 in ischemic brain has been delineated by using alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490) as a selective JAK2/STAT3 inhibitor \[[@B13][@B14][@B15]\]. Gap junctions are the intercellular channels and these allow the communication between the adjacent cells. Connexin 43 is an important constituent protein of the gap junction channels and connexin 43 is widely distributed in the central nervous system including astrocytes, neuronal precursors and neurons \[[@B16][@B17]\]. Moreover, studies have reported the key role of connexin 43 in cerebral injury and accordingly, scientists have projected connexin 43 as a key therapeutic target in inducing tissue protection \[[@B18][@B19][@B20]\]. The present study was aimed to explore the neuroprotective role of imatinib in global ischemia-reperfusion-induced cerebral injury along with possible mechanisms involving JAK3/STAT3 and connexin 43.

METHODS
=======

Experimental animals, chemicals and drugs
-----------------------------------------

Swiss albino male mice (20--25 g) were used for this study. The experimental studies pertaining to animals were approved by Animal Ethics Committee of Shaanxi Provincial People\'s Hospital (no. 201905-1301) and all experiments were done according to ethical guidelines. The enzyme-linked immunosorbent assay (ELISA) kit for the quantitative estimation of phosphorylated (p)-STAT3 was procured from Abcam, Cambridge, MA, USA, while the ELISA kit for connexin 43 was procured from LifeSpan Bio-Sciences, Seattle, WA, USA. Imatinib mesylate (Sigma Aldrich, St. Louis, MO, USA) was dissolved in normal saline, while AG490 (Sigma Aldrich) was dissolved in 2% dimethyl sulfoxide and their doses were selected on the basis of previously published reports \[[@B21][@B22][@B23][@B24]\].

Global ischemia reperfusion injury to mice brain
------------------------------------------------

Thiopental sodium (45 mg/kg i.p.) was administered to anesthetize mice. Thereafter, surgery was performed to occlude both carotid arteries for 20 min and induce global ischemic injury. It was followed by reperfusion injury in which occlusion was removed and the blood flow to the brain was restored for 24 h \[[@B25][@B26]\].

Behavioral assessment of extent of ischemia-reperfusion-induced cerebral injury
-------------------------------------------------------------------------------

The extent of ischemia-reperfusion injury was assessed by using a battery of behavioral tests to evaluate the locomotion, motor coordination and cognition. The locomotor activity was assessed using an actophotometer test for 10 min and activity was recorded in scores. The inclined beam walking test was used to evaluate the fore- and hind limb motor coordination in which mice were allowed to walk on an inclined (at an angle of 60°) metallic bar of 60 cm length and 1.5 cm width. The scoring between 0--4 was done on the basis of their performance on the metallic, with the lowest score indicating no defect and highest score indicating the maximum defect. The total neurological deficit was also assessed by giving the scores from 0--10, with lowest score indicating the normal and maximum score indicating the most severe form \[[@B27][@B28]\].

Since ischemia-reperfusion injury produces severe motor deficits, therefore, the memory of animals was evaluated using the object recognition test, in which memory evaluation is independent of motor activity \[[@B29][@B30]\]. In this test, animals were subjected to 3 sessions including 'habituation' on day 0 (i.e., a day before surgery), 'familiarization' on day 1 (i.e., on a day of surgery, but performed before doing surgery) and 'test' on day 2 (i.e., 24 h after surgery, before sacrificing mice). In habituation, animals were kept in an arena for five minutes and in familiarization, 2 different objects were placed in the arena and mice explored those objects for 5 min. On the test day, one of the objects was replaced with a new object and mice were allowed to explore those objects for 5 min. Depending on the difference in time spent by mice in exploring new and the familiar object, the discrimination index was calculated by the following formula:

Discrimination index = (T~Novel~ − T~Familiar~) / (T~Novel~ + T~Familiar~) × 100%

Assessment of biochemical parameters in the brain homogenate
------------------------------------------------------------

After performing the behavioral tests, the animals were sacrificed by cervical dislocation to remove the brains. The brain was homogenized in the freshly prepared phosphate buffer (pH = 7.4) and centrifuged to obtain the supernatant. The different biochemical tests were performed in the brain homogenate supernatant. The levels of p-STAT3 and connexin 43 were estimated in the brain homogenate using commercially available ELISA kits and estimations were done as per instructions of the kit.

Assessment of cerebral infarction
---------------------------------

The mice brains were kept in refrigerator and thereafter, these were cut into thin slices. These were stained using triphenyl tetrazolium chloride (TTC) and cerebral infarction was calculated depending on the differential staining of infarcted and viable brain portions \[[@B31]\].

Experimental design
-------------------

Seven groups (n = 8) were employed in this present study and details of these groups is explained below.

**I. Normal:** Animals were not subjected to any intervention and the different tests were performed in the normal mice.

**II. Sham:** The carotid arteries were exposed and thread was passed below the arteries, without any occlusion. Afterwards, the sutures were made to close the wound and animals were kept for 24 h. The different behavioral and biochemical tests were performed in these animals before subjecting to surgery and 24 h after performing surgery.

**III. Ischemia-reperfusion injury:** After surgery, both the carotid arteries were occluded to induce global ischemia for 20 min, which was followed by reperfusion for 24 h by de-occluding the carotid arteries. The different behavioral and biochemical tests were performed in these animals before subjecting to surgery and 24 h after performing surgery.

**IV and V. Imatinib (20 and 40 mg/kg) in ischemia-reperfusion injury:** Two different doses of imatinib (20 mg/kg i.p.) and (40 mg/kg i.p.) were administered in two different groups, 30 min prior to subjecting to ischemia-reperfusion injury. The different behavioral and biochemical tests were performed in these animals before subjecting to surgery and 24 h after performing surgery.

**VI and VII. AG490 (3 and 6 mg/kg) in imatinib (40 mg/kg) treated ischemia-reperfusion injury:** AG490 (3 and 6 mg/kg i.p.) was administered 30 min prior to imatinib (40 mg/kg i.p.) treatment in ischemia-reperfusion-subjected mice. The different behavioral and biochemical tests were performed in these animals before subjecting to surgery and 24 h after performing surgery.

Statistical analysis
--------------------

The results of the study were denoted as mean ± standard deviation. The data were analyzed using One way ANOVA followed by Bonferroni *post hoc* test. The value of p \< 0.05 was considered to statistically significant.

RESULTS
=======

Impairment in locomotor activity, motor incoordination, development of neurological deficits, impairment in memory and cerebral injury in global ischemia-reperfusion-subjected mice
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

There was a marked reduction in the locomotor activity (decrease in score in an actophotometer test) ([Fig. 1A](#F1){ref-type="fig"}); motor incoordination (increase in score in the inclined beam walking test) ([Fig. 1B](#F1){ref-type="fig"}), development of neurological deficits (increase in neurological severity score) ([Fig. 2A](#F2){ref-type="fig"}) along with decease in learning and memory (decrease in discrimination index in object recognition test) ([Fig. 3](#F3){ref-type="fig"}) following 20 min of global ischemia and 24 h of reperfusion injury. Moreover, global ischemia and reperfusion led to significant cerebral injury assessed in terms of increase in cerebral infarction. Indeed in ischemia-reperfusion subjected mice, there was marked increase in cerebral infarction assessed using TTC staining in comparison to sham control mice ([Fig. 2B](#F2){ref-type="fig"}).

Influence of pharmacological modulators on ischemia-reperfusion-induced alterations in behavioral parameters and cerebral infarction
------------------------------------------------------------------------------------------------------------------------------------

Administration of a single dose of imatinib (20 and 40 mg/ kg i.p.) led to dose-dependent improvement in behavioral alterations induced due to global ischemia and reperfusion. There was an improvement in the locomotor activity, motor coordination, decrease in neurological severity score, increase in discrimination index (memory test) and decrease in cerebral infarction in imatinib-treated mice. However, prior administration of AG490 significantly abolished imatinib-mediated improvement in behavioral parameters in ischemia-reperfusion-subjected mice. The improvement in locomotor activity ([Fig. 1A](#F1){ref-type="fig"}), motor coordination ([Fig. 1B](#F1){ref-type="fig"}), neurological deficits ([Fig. 2A](#F2){ref-type="fig"}), learning and memory ([Fig. 3](#F3){ref-type="fig"}) imparted in the presence of imatinib was attenuated with the prior administration of AG490. Moreover, AG490 also attenuated imatinib-mediated decrease in cerebral infarction in global ischemia-reperfusion injury subjected mice ([Fig. 2B](#F2){ref-type="fig"}).

Changes in the biochemical parameters in the brain homogenate due to ischemia-reperfusion injury and pharmacological modulators
-------------------------------------------------------------------------------------------------------------------------------

There was a significant decrease in the expression of connexin 43 and p-STAT3 in the brain homogenate following 20 min of global ischemia and 24 h of reperfusion. However, imatinibmediated improvement in behavioral parameters and decrease in cerebral infarction was also associated with the normalization of biochemical alterations in ischemia-reperfusion-subjected mice. Treatment with imatinib (20 and 40 mg/kg) led to normalization of connexin 43 and p-STAT3 expression in the brain. However, prior administration of AG490 attenuated the effects of imatinib on the biochemical parameters and there was significant decrease in the expression of connexin 43 ([Fig. 4A](#F4){ref-type="fig"}) and p-STAT3 ([Fig. 4B](#F4){ref-type="fig"}) in AG490 administered mice.

DISCUSSION
==========

Since there is a significant influence of cyclical variations of circulating estrogen levels on the cerebral ischemia-reperfusion injury \[[@B32],[@B33]\], therefore, male mice were employed in the present study. In this study, 20 min of global cerebral ischemia and 24 h of reperfusion led to significant brain injury, assessed in terms of decrease in the locomotor activity, development of motor incoordination and neurological deficits. Moreover, there was a significant decline in learning and memory in ischemia-reperfusion-subjected mice assessed by measuring discrimination index using a discrimination test. The assessment of learning and memory using a discrimination test is advantageous as this test is minimally dependent on the locomotor activity, which is in contrast to typical maze tests in which assessment of memory is dependent on locomotor activity \[[@B34][@B35]\]. Due to this, discrimination-based memory test is particularly useful in situations in which there is a locomotor impairment such as in this present study. Apart from these, global ischemia and reperfusion also led to increase in the cerebral infarction, assessed using TTC staining ([Fig. 5](#F5){ref-type="fig"}).

In the present investigation, treatment with a single dose of imatinib (20 and 40 mg/kg) significantly attenuated global ischemia-reperfusion injury-induced cerebral injury in terms of improvement in behavioral parameters, normalization of learning and memory along with decrease in cerebral infarction. Imatinib is an anticancer drug and it has been used in different cancers including chronic myeloid leukemia and gastrointestinal stromal tumor \[[@B1][@B2]\]. Furthermore, preclinical and clinical studies have shown the beneficial role of imatinib in the different diseases affecting the brain including Alzheimer disease, Parkinson disease and multiple sclerosis \[[@B3][@B36]\]. Moreover, its efficacy in attenuating acute ischemic stroke \[[@B6]\], tissue Plasminogen activator \[[@B7]\], subarachnoid hemorrhage \[[@B9]\], intracerebral hemorrhage \[[@B10]\] and traumatic brain injury \[[@B8]\]-induced blood brain barrier disruption has also been reported. However to best of our knowledge, it is the first research study depicting the potential of imatinib in attenuating global ischemia-reperfusion-induced cerebral infarction, decline in memory along with behavioral and neurological deficits.

In the present study, there was a significant decrease in the levels of p-STAT3 and connexin 43 in the brains of the mice subjected to 20 min of global ischemia and 24 h of reperfusion. STAT3 is a transcriptional factor and it belongs to the family of STAT proteins. Activation of JAK2 leads to the phosphorylation of STAT3, which in turn is translocated in the nucleus to influence the protein expression. There have been previous studies showing a decrease in the levels of p-STAT3 in the brain in response to ischemia-reperfusion injury and increase in the expression of p-STAT3 is associated with neuroprotective effects \[[@B37][@B38]\]. Studies have shown that the increase in the expression of STAT3, a transcriptional factor, is associated with a decrease in inflammatory mediators \[[@B39]\]. Indeed, the actions of anti-inflammatory cytokine (interleukin-10) are mediated through activation of JAK2/STAT3 pathway \[[@B40][@B41]\]. Connexin 43 is a gap junction protein and it forms the structural unit of gap junctions, predominantly in the central nervous system. Studies have shown that connexin 43-dependent gap junctional channels play an important role in maintaining the communication amongst different neurons and hence, these are critical in maintaining brain homeostasis \[[@B42]\]. Moreover, studies have shown the protective role of connexin 43 and it has been projected as a key therapeutic target to confer tissue protection \[[@B19][@B43][@B44]\]. It is reported that connexin 43 produces neuroprotection by virtue of multiple effects including decreased release of pro-inflammatory factors from microglial cells \[[@B45]\] and maintaining the functional status of mitochondria \[[@B46]\]. Indeed, mice lacking connexin 43 in astrocytes exhibit an increase in apoptosis and neuroinflammation following cerebral ischemia \[[@B47]\].

In this study, treatment with a single dose of imatinib significantly attenuated ischemia-reperfusion-induced decrease in the levels of p-STAT3 and connexin 43 in the brain. Accordingly, it may be suggested that imatinib-mediated beneficial effects are possibly mediated through activation of p-STAT3 and connexin 43 signaling pathway. The relationship between imatinib and p-STAT3 was further established by the results of this study showing that the beneficial effects of imatinib were significantly attenuated in the presence of AG490, a selective JAK-STAT3 inhibitor. Administration of AG490 significantly attenuated the beneficial effects of imatinib in global ischemia-reperfusion-induced behavioral changes, neurological deficits, cerebral infarction and decline in memory. It suggests the importance of JAK-STAT3 signaling pathway activation in triggering neuroprotection in response to imatinib treatment. There have been previous studies showing that the activation of JAK2/STAT3 signaling pathway triggers neuroprotection in different models \[[@B14][@B15]\].

Apart from attenuating the beneficial effects of imatinib, administration of AG490 also attenuated the levels of p-STAT3 and connexin 43 in imatinib-treated mice. The decrease in the p-STAT3 levels in the presence of AG490 signifies that JAK2 activation is responsible for increasing the levels of phosphorylated form of STAT3. The decrease in the levels of connexin 43 in the presence of AG490 signifies that the expression of connexin 43 is dependent on the activation of JAK-STAT3 pathway and connexin 43 is a downstream mediator of JAK-STAT3 signaling pathway. A previous study had also demonstrated that an increase in connexin 43 is dependent on the activation of JAK/STAT pathway \[[@B48]\]. Based on this, it may be proposed that imatinib-mediated neuroprotective effects in global ischemia reperfusion injury may involve activation of the JAK2/STAT3 signaling pathway along with the increase in the expression of connexin 43 ([Fig. 6](#F6){ref-type="fig"}).

It is an interesting finding that imatinib, being a tyrosine kinase inhibitor, promoted the activation of JAK2/STAT3 pathway and increased the levels of phosphorylated form of STAT3. However, the results of the present study are not sufficient enough to delineate the precise mechanisms responsible for increase in the phosphorylated form of STAT3 and activation of JAK2 pathway in the presence of imatinib. The activation of JAK2/STAT3 pathway is linked to multiple pathways including glycogen synthase kinase (GSK)-3β \[[@B49][@B50]\]. It is also reported that imatinib decreases the phosphorylation of GSK-3β and increases the enzyme activity of GSK-3β \[[@B51][@B52]\]. Moreover, there has been a report suggesting that the activation of JAK2 is negatively regulated by a scaffolding protein 'ninein' \[[@B53]\], which in turn is phosphorylated in the presence of GSK-3β \[[@B54]\]. Accordingly, it may be hypothesized that imatinib-mediated decrease in phosphorylation of GSK-3β and increase in GSK-3β activity may activate the JAK2 pathway leading to increase in the phosphorylation of STAT3. However, future studies are required to experimentally verify the above described hypothesis that imatinib may activate the GSK-3β activity to trigger the activation of JAK2/STAT3 signaling pathway in inducing neuroprotection in cerebral ischemia-reperfusion injury model.

Imatinib has the therapeutic potential in attenuating global ischemia reperfusion-induced cerebral injury, which may be possibly attributed to activation of JAK2/STAT3 signaling pathway along with the increase in the expression of connexin 43.
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![Influence of global ischemia-reperfusion (I/R) injury and pharmacological modulators.\
(A) Locomotor activity assessed in the actophotometer test and (B) motor coordination assessed using inclined beam walking test. Values are represented in mean ± standard deviation. ^\*^p \< 0.05 *vs.* normal; ^\*\*^p \< 0.05 *vs.* ischemia-reperfusion I/R injury; ^\*\*\*^p \< 0.05 *vs.* imatinib (20 mg/kg) in I/R injury; ^@^p \< 0.05 *vs.* imatinib (40 mg/kg) in I/R injury.](kjpp-24-11-g001){#F1}

![Influence of global ischemia-reperfusion (I/R) injury and pharmacological modulators.\
(A) Neurological severity score and (B) cerebral infarction. Values are represented in mean ± standard deviation. ^\*^p \< 0.05 *vs.* normal; ^\*\*^p \< 0.05 *vs.* ischemia-reperfusion I/R injury; ^\*\*\*^p \< 0.05 *vs.* imatinib (20 mg/kg) in I/R injury; ^@^p \< 0.05 *vs.* imatinib (40 mg/kg) in I/R injury.](kjpp-24-11-g002){#F2}

![Influence of global ischemia-reperfusion (I/R) injury and pharmacological modulators on discrimination index as a parameter of learning and memory assessed using object recognition test.\
Values are represented in mean ± standard deviation. ^\*^p \< 0.05 *vs.* normal; ^\*\*^p \< 0.05 *vs.* I/R injury; ^\*\*\*^p \< 0.05 *vs.* imatinib (20 mg/kg) in I/R injury; ^@^p \< 0.05 *vs.* imatinib (40 mg/kg) in I/R injury.](kjpp-24-11-g003){#F3}

![Influence of global ischemia-reperfusion (I/R) injury and pharmacological modulators.\
(A) Connexin 43 levels and (B) phosphorylated signal transducer and activator of transcription 3 (p-STAT3) levels in the brain homogenate. Values are represented in mean ± standard deviation. ^\*^p \< 0.05 *vs.* normal; ^\*\*^p \< 0.05 *vs.* I/R injury; ^\*\*\*^p \< 0.05 *vs.* imatinib (20 mg/kg) in I/R injury; ^@^p \< 0.05 *vs.* imatinib (40 mg/kg) in I/R injury.](kjpp-24-11-g004){#F4}

![Representaive pictures of TTC-stained brain slices for determining the extent of cerebral infarction.\
TTC, triphenyl tetrazolium chloride.](kjpp-24-11-g005){#F5}

![Proposed hypothesis of imatinib-induced neuroprotection in cerebral ischemia-reperfusion induced injury.\
p-STAT3, phosphorylated signal transducer and activator of transcription 3; JAK2, Janus-activated kinase 2.](kjpp-24-11-g006){#F6}
